BRIEF --EMA publishes Business Continuity Plan for Brexit

The European Medicines Agency has published its Brexit Preparedness Business Continuity Plan. The plan, which was endorsed by the Management Board at its June 2017 meeting, aims to safeguard continuity of EMA’s operations to protect public health while the Agency prepares for its relocation to a new host city and the departure of the United Kingdom from the European Union (EU).

The EMA’s Business Continuity Plan is an essential tool to deal with the uncertainty and workload implications linked to the UK’s withdrawal from the EU and the Agency’s relocation from its current base in London.

It describes the methodology by which EMA has categorised and prioritised its activities and how it plans to reallocate resources to its core activities if needed. The plan prioritises tasks and activities and classifies them into three categories according to their impact on public health and the Agency’s ability to function.

The plan will be continuously reviewed and adapted as necessary.